刘享享，女，2024年6月毕业于东北师范大学细胞生物学专业，获理学博士学位。2024年9月进入雷竞技raybet官方平台雷竞技raybet官方平台工作。主要从事肿瘤相关基因沉默和活化的表观遗传调控以及表观修饰酶抑制剂的筛选及抗肿瘤活性的研究。近年来以第一作者身份在《Cancer Letters》、《International Journal of Molecular Sciences》、《Cell Death Discovery》、《Mitochondrial DNA B Resources》等学术期刊上发表论文多篇。

近年来发表的代表性论文：

[1] Liu X, et al. Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation. Cancer Lett. 2024. 586:216707.

[2] Liu X, et al. A Novel Class I HDAC Inhibitor, AW01178, Inhibits Epithelial-Mesenchymal Transition and Metastasis of Breast Cancer. Int J Mol Sci. 2024. 25(13):7234.

[3] Liu X, et al. The complete mitogenome of one commercial Saccharina cultivar in Chinese market and its evaluation of genetic relationship. Mitochondrial DNA B Resour. 2018. 3(2):590-591.

[4] Kong SH, Ma L, Yuan Q, Liu X, et al. Inhibition of EZH2 alleviates SAHAinduced senescence-associated secretion phenotype in small cell lung cancer cells. Cell Death Discov. 2023. 9(1):289.